Last reviewed · How we verify

Copharos — Portfolio Competitive Intelligence Brief

Copharos pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Astellas Pharma Global Development, Inc. · 1 shared drug class
  2. Children's Cancer Group, China · 1 shared drug class
  3. Eastern Cooperative Oncology Group · 1 shared drug class
  4. GlaxoSmithKline · 1 shared drug class
  5. Merck Sharp & Dohme LLC · 1 shared drug class
  6. Mirati Therapeutics Inc. · 1 shared drug class
  7. NYU Langone Health · 1 shared drug class
  8. RemeGen Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Copharos:

Cite this brief

Drug Landscape (2026). Copharos — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/copharos. Accessed 2026-05-13.

Related